{
    "clinical_study": {
        "@rank": "137668", 
        "arm_group": [
            {
                "arm_group_label": "TR", 
                "arm_group_type": "Experimental", 
                "description": "HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal"
            }, 
            {
                "arm_group_label": "RT", 
                "arm_group_type": "Experimental", 
                "description": "coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10\n      mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102"
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male\n\n          -  Age between 20 and 55\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Has a history of hypersensitivity to IP ingredients\n\n          -  Hypotension or hypertension\n\n          -  Has a history of acute infection within 14 days of screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651481", 
            "org_study_id": "HM-MOLZ-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TR", 
                    "RT"
                ], 
                "intervention_name": "HCP1102", 
                "intervention_type": "Drug", 
                "other_name": "Singulair and Xyzal combination tablet"
            }, 
            {
                "arm_group_label": [
                    "TR", 
                    "RT"
                ], 
                "intervention_name": "Singulair and Xyzal", 
                "intervention_type": "Drug", 
                "other_name": "coadministration of Singulair and Xyzal"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Montelukast", 
                "Levocetirizine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Rhinitis", 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung medical center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "0-34hr"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "0-34hr"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "0-34hr"
            }, 
            {
                "measure": "AUCinf", 
                "safety_issue": "No", 
                "time_frame": "0-34hr"
            }, 
            {
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "0-34hr"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}